These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15687926)

  • 21. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.
    Shin DH; Glover BK; Cha SC; Kim YY; Kim C; Nguyen KD
    Am J Ophthalmol; 1999 May; 127(5):511-5. PubMed ID: 10334342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The ocular hypotensive effect and safety of 0.2% brimonidine].
    Yu M; Li Y; Ge J
    Yan Ke Xue Bao; 2001 Dec; 17(4):235-8. PubMed ID: 12567513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The adverse effect of perioperative brimonidine tartrate 0.2% on flap adherence and enhancement rates in laser in situ keratomileusis patients.
    Walter KA; Gilbert DD
    Ophthalmology; 2001 Aug; 108(8):1434-8. PubMed ID: 11470696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II.
    Melamed S; David R
    Clin Ther; 2000 Jan; 22(1):103-11. PubMed ID: 10688394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allergic reactions to brimonidine in patients treated for glaucoma.
    Blondeau P; Rousseau JA
    Can J Ophthalmol; 2002 Feb; 37(1):21-6. PubMed ID: 11865954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma.
    Korsch E; Grote A; Seybold M; Soditt V
    Eur J Pediatr; 1999 Aug; 158(8):685. PubMed ID: 10445353
    [No Abstract]   [Full Text] [Related]  

  • 27. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.
    DuBiner HB; Mroz M; Shapiro AM; Dirks MS;
    Clin Ther; 2001 Dec; 23(12):1969-83. PubMed ID: 11813932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.
    Adkins JC; Balfour JA
    Drugs Aging; 1998 Mar; 12(3):225-41. PubMed ID: 9534022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans.
    Schadlu R; Maus TL; Nau CB; Brubaker RF
    Arch Ophthalmol; 1998 Nov; 116(11):1441-4. PubMed ID: 9823343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty.
    David R; Spaeth GL; Clevenger CE; Perell HF; Siegel LI; Henry JC; Stiles MC; Passo MS; Stamper RL; Walt JG
    Arch Ophthalmol; 1993 Oct; 111(10):1387-90. PubMed ID: 8105773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension.
    Schuman JS
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S27-37. PubMed ID: 8970247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III.
    Serle JB
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S39-47. PubMed ID: 8970248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute and chronic effects of brimonidine 0.2% on intraocular pressure and pulsatile ocular blood flow in patients with primary open-angle glaucoma: an open-label, uncontrolled, prospective study.
    Vetrugno M; Maino A; Cantatore F; Ruggeri G; Cardia L
    Clin Ther; 2001 Sep; 23(9):1519-28. PubMed ID: 11589264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Charles Bonnet syndrome precipitated by brimonidine tartrate eye drops.
    Tomsak RL; Zaret CR; Weidenthal D
    Br J Ophthalmol; 2003 Jul; 87(7):917. PubMed ID: 12812898
    [No Abstract]   [Full Text] [Related]  

  • 35. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1.
    Whitson JT; Ochsner KI; Moster MR; Sullivan EK; Andrew RM; Silver LH; Wells DT; James JE; Bosworth CF; Dickerson JE; Landry TA; Bergamini MV;
    Ophthalmology; 2006 Aug; 113(8):1333-9. PubMed ID: 16877072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic side effects of ophthalmic drops.
    Levy Y; Zadok D
    Clin Pediatr (Phila); 2004; 43(1):99-101. PubMed ID: 14968900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brimonidine (Alphagan): a clinical profile four years after launch.
    David R
    Eur J Ophthalmol; 2001; 11 Suppl 2():S72-7. PubMed ID: 11592536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The teardrop sign: a rare dermatological reaction to brimonidine.
    Scruggs JT; Whiteside-Michel J; Brodsky MC
    Br J Ophthalmol; 2000 Jun; 84(6):671-2. PubMed ID: 10896417
    [No Abstract]   [Full Text] [Related]  

  • 39. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure.
    Stewart WC; Sharpe ED; Harbin TS; Pastor SA; Day DG; Holmes KT; Stewart JA
    Am J Ophthalmol; 2000 Jun; 129(6):723-7. PubMed ID: 10926979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is brimonidine ophthalmic a safe therapy for infants?
    Daubert GP
    J Clin Pharm Ther; 2006 Jun; 31(3):289-92. PubMed ID: 16789995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.